Full text is available at the source.
Abstract
Limited research exists on the interactions between glucagon-like peptide-1 receptor agonists and the gut microbiome.
- Glucagon-like peptide-1 receptor agonists may influence body weight and dietary habits.
- Changes in behavior and diet are suggested to drive alterations in the gut microbiome following treatment with GLP-1 RAs.
- Significant gaps in knowledge exist regarding the role of diet in the effects of GLP-1 RA therapy on the gut microbiome.
- Proposed relationships between GLP-1 RAs, the gut microbiome, and obesity management require further investigation.
Simplified